Abstract:Objective To investigate the expression and clinical significance of CD10, CD133 and CD157 in gastric cancer. Methods We selected 105 cases of gastric cancer tissue samples surgically removed in Yiwu Central Hospital from March 2016 to March 2019, and adjacent normal tissues ≥5cm away from the edge of the tumor were taken as control samples. The expression of CD10, CD133 and CD157 protein in cancer tissues and adjacent normal tissues was detected by immunohistochemical staining. The patients were followed up until September 30, 2020. The death of the patients was taken as the endpoint event, and the overall survival (OS) was calculated. Results The positive rates of CD10, CD133 and CD157 protein expression in cancer tissues were higher than those in adjacent normal tissues (P < 0.05). The OS of patients with positive expression of CD10, CD133 and CD157 was better than that of patients with negative expression of these molecules (P < 0.05). Age [R^R = 1.628 (95% CI: 1.218, 2.940)], TNM stage [R^R = 1.982 (95% CI: 1.435, 3.495)], depth of invasion [R^R = 2.653 (95% CI: 1.782, 4.213)], lymph node metastasis [R^R = 3.287 (95% CI: 1.989, 5.456)], positive expression of CD10 [R^R = 2.081 (95% CI: 1.297, 3.241)], positive expression of CD133 [R^R = 1.768 (95% CI: 1.190, 2.879)] and positive expression of CD157 [R^R = 2.463 (95% CI: 1.797, 4.165)] were independent risk predictors of gastric cancer (P < 0.05). Conclusion The CD10, CD133 and CD157 are highly expressed in gastric cancer, and closely related to lymph node metastasis and prognosis.